Our Science

PBH is a form of reactive hypoglycemia that usually presents 6 months to 4 years post-surgery and is caused by increased postprandial circulating glucose and a resulting uncontrolled spike in insulin, typically occurring 1-2 hours after a meal. Symptoms can include those associated with neuroglycopenia such as weakness, drowsiness, dizziness, confusion, seizure and loss of consciousness that can dangerously impair normal day-to-day activities and can sometimes be life-threatening. 

Mizagliflozin, a small molecule therapeutic targeted at PBH, a metabolic disease with a growing high unmet medical need. Mizagliflozin is a minimally absorbed inhibitor of SGLT1 being developed by Vogenx for the treatment of PBH. 

Our Clients/Parteners

Research & Development

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.